TY - JOUR
T1 - FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma
AU - Kandathil, Asha
AU - Subramaniam, Rathan M.
N1 - Funding Information:
Declaration of interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/11
Y1 - 2022/11
N2 - Lung cancer is the leading cause of cancer-related mortality in the United States. Accurate staging at initial diagnosis determines appropriate treatment and is the most important predictor of survival. Since 2018, the 8th edition of the TNM staging system has been used to stage lung cancer based on local tumor extent (T), nodal involvement (N), and metastases (M). 18 F fluorodeoxyglucose (FDG) PET/CT, which combines functional and anatomic imaging, is the standard of care and an integral part of clinical staging of patients with lung cancer. Malignant pleural mesothelioma (MPM), the most common primary malignant pleural tumor affecting the pleura is staged with 8th edition of TNM staging for MPM. 18 F FDG PET/CT is indicated in select patients who are surgical candidates to identify locally advanced tumor, nodal metastases, or extrathoracic metastases, which may preclude surgery.
AB - Lung cancer is the leading cause of cancer-related mortality in the United States. Accurate staging at initial diagnosis determines appropriate treatment and is the most important predictor of survival. Since 2018, the 8th edition of the TNM staging system has been used to stage lung cancer based on local tumor extent (T), nodal involvement (N), and metastases (M). 18 F fluorodeoxyglucose (FDG) PET/CT, which combines functional and anatomic imaging, is the standard of care and an integral part of clinical staging of patients with lung cancer. Malignant pleural mesothelioma (MPM), the most common primary malignant pleural tumor affecting the pleura is staged with 8th edition of TNM staging for MPM. 18 F FDG PET/CT is indicated in select patients who are surgical candidates to identify locally advanced tumor, nodal metastases, or extrathoracic metastases, which may preclude surgery.
UR - http://www.scopus.com/inward/record.url?scp=85132841237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132841237&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2022.04.011
DO - 10.1053/j.semnuclmed.2022.04.011
M3 - Review article
C2 - 35738910
AN - SCOPUS:85132841237
SN - 0001-2998
VL - 52
SP - 650
EP - 661
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 6
ER -